Dose and timing of interleukin (IL)-12 and timing and type of total-body irradiation: effects on graft-vs.-host disease inhibition and toxicity of exogenous IL-12 in murine bone marrow transplant recipients.

[1]  R. Caspi,et al.  Interleukin 12 Protects from a T Helper Type 1–mediated Autoimmune Disease, Experimental Autoimmune Uveitis, through a Mechanism Involving Interferon γ, Nitric Oxide, and Apoptosis , 1999, The Journal of experimental medicine.

[2]  D. Taub,et al.  Differential effects of the absence of interferon-gamma and IL-4 in acute graft-versus-host disease after allogeneic bone marrow transplantation in mice. , 1998, The Journal of clinical investigation.

[3]  G. Szot,et al.  Interleukin-12 inhibits graft-versus-host disease through an Fas-mediated mechanism associated with alterations in donor T-cell activation and expansion. , 1998, Blood.

[4]  G. Szot,et al.  Interleukin-12 preserves the graft-versus-leukemia effect of allogeneic CD8 T cells while inhibiting CD4-dependent graft-versus-host disease in mice. , 1997, Blood.

[5]  B. Blazar,et al.  CD4+ and CD8+ T cells each can utilize a perforin-dependent pathway to mediate lethal graft-versus-host disease in major histocompatibility complex-disparate recipients. , 1997, Transplantation.

[6]  M. Atkins,et al.  Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  R. Flavell,et al.  Blockade of CD40 ligand-CD40 interaction impairs CD4+ T cell-mediated alloreactivity by inhibiting mature donor T cell expansion and function after bone marrow transplantation. , 1997, Journal of immunology.

[8]  M. Eckhaus,et al.  Allospecific CD8+ Tc1 and Tc2 populations in graft-versus-leukemia effect and graft-versus-host disease. , 1996, Journal of immunology.

[9]  J. Bradley,et al.  IL-12 is a central mediator of acute graft-versus-host disease in mice. , 1996, Journal of immunology.

[10]  T. Ley,et al.  The role of granzyme B in murine models of acute graft-versus-host disease and graft rejection. , 1996, Blood.

[11]  J. Tschopp,et al.  Cytotoxic T cells deficient in both functional fas ligand and perforin show residual cytolytic activity yet lose their capacity to induce lethal acute graft-versus-host disease , 1996, The Journal of experimental medicine.

[12]  B. Collins,et al.  THE HUMORAL IMMUNE RESPONSE IN HUMANS FOLLOWING CROSS‐PERFUSION OF PORCINE ORGANS , 1995, Transplantation.

[13]  G. Szot,et al.  Interleukin-12 inhibits murine graft-versus-host disease. , 1995, Blood.

[14]  W. Gause,et al.  Kinetics of Th1 and Th2 cytokine production during the early course of acute and chronic murine graft-versus-host disease. Regulatory role of donor CD8+ T cells. , 1995, Journal of immunology.

[15]  J. Orange,et al.  Mechanism of interleukin 12-mediated toxicities during experimental viral infections: role of tumor necrosis factor and glucocorticoids , 1995, The Journal of experimental medicine.

[16]  M. Berger,et al.  T cell subsets involved in lethal graft-versus-host disease directed to immunodominant minor histocompatibility antigens. , 1994, Transplantation.

[17]  John S. Thompson,et al.  Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2- incompatible transplanted SCID mice , 1994 .

[18]  J. Vossen,et al.  Interferon-gamma prevents graft-versus-host disease after allogeneic bone marrow transplantation in mice. , 1993, Journal of immunology.

[19]  C. Sidman,et al.  Differential cytokine expression in acute and chronic murine graft‐versus‐host‐disease , 1993, European journal of immunology.

[20]  M. Sykes,et al.  IL-2 reduces graft-versus-host disease and preserves a graft-versus-leukemia effect by selectively inhibiting CD4+ T cell activity. , 1993, Journal of immunology.

[21]  S. Feig,et al.  Selective depletion of CD8+ T lymphocytes for prevention of graft-versus-host disease after allogeneic bone marrow transplantation. , 1990, Blood.

[22]  A. Zwinderman,et al.  EFFECTOR MECHANISMS IN GRAFT‐VERSUS-HOST DISEASE IN RESPONSE TO MINOR HISTOCOMPATIBILITY ANTIGENS: I. ABSENCE OF CORRELATION WITH CYTOTOXIC EFFECTOR CELLS , 1990, Transplantation.

[23]  T. Sundt,et al.  Effects of T cell depletion in radiation bone marrow chimeras. III. Characterization of allogeneic bone marrow cell populations that increase allogeneic chimerism independently of graft-vs-host disease in mixed marrow recipients. , 1989, Journal of immunology.

[24]  B. Blazar,et al.  The effect of T subset depletion on the incidence of lethal graft-versus-host disease in a murine major-histocompatibility-complex-mismatched transplantation system. , 1987, Transplantation.

[25]  R. Epstein,et al.  Radiation-induced hemopoietic death in mice as a function of photon energy and dose rate. , 1986, Radiation research.

[26]  M. Bevan,et al.  Anti-recipient cytotoxic T lymphocyte precursors are present in the spleens of mice with acute graft versus host disease due to minor histocompatibility antigens. , 1981, Journal of immunology.

[27]  N. Mantel.  Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.

[28]  M. Atkins,et al.  Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.